Evaluation of the Pharmacokinetics of Nafamostat Mesylate during Continuous Renal Replacement Therapy

• Material Type: 博士論文
• Title: Evaluation of the Pharmacokinetics of Nafamostat Mesylate during Continuous Renal Replacement Therapy
• Author/Editor: Konishi, Koji; Inoue, Satoki; Kawaguchi, Masahiko
• Author Heading: Konishi, Koji; Inoue, Satoki; Kawaguchi, Masahiko
• Publication, Distribution, etc.: Scientific Research
• Publication Date: 2022-12
• Publication Date (W3CDTF): 2022-12
• Alternative Title: 持続的腎代替療法におけるメシル酸ナファモスタットの血中動態
• Periodical title: Emergency Medicine
• No. or year of volume/issue: 10 4
• Volume: 10
• Issue: 4
• Pages: 157-167
• ISSN (Periodical Title): ISSN : 2332-1806
• Degree grantor/type: 奈良県立医科大学
• Date Granted: 2023-03-15
• Dissertation Number: 乙第1531号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: Nafamostat Mesylate; Continuous Renal Replacement Therapy; Liver Dysfunction
• Target Audience: 一般
• Note (General): type:Thesis; Continuous renal replacement therapy (CRRT) is the preferred dialysis modality in critical care settings for patients with hemodynamic instability. Nafamostat mesylate (NM) is an anticoagulant commonly used (mainly in Japan) during CRRT in patients with high bleeding risk. In this study, we evaluated the pharmacokinetics of NM during CRRT. Patients undergoing CRRT therapy and using NM as the anticoagulant in the intensive care unit were enrolled in the study. Blood was collected from the CRRT circuit just after blood removal, just before and after the membrane for CRRT, and from the filtrates after the membrane. NM concentrations were measured using high-performance liquid chromatography. NM was detected in the intracorporeal circulation during CRRT in some cases, and liver enzymes were severely elevated in almost all of the cases. Coagulation time was prolonged even before the initiation of NM administration in these cases and may be associated with liver damage. This study suggests that NM dosage should take into account liver damage assessed by elevated liver enzymes.; 博士（医学）・乙第1531号・令和5年3月15日; © 2022 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).; identifier:Emergency Medicine Vol.10 No.4 p.157-167 (2022 Dec); identifier:23321806; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/4116; identifier:Emergency Medicine, 10(4): 157-167
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.4236/ojem.2022.104014
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

Table of Contents

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4116/1/01%e4%b9%991531%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4116/2/02%e4%b9%991531%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4116/6/03%e4%b9%991531%e6%9c%ac%e6%96%87.pdf fulltext